Treatment of chronic hep- atitis B in the human immunodeficiency virus-infected patient: present and future. Clin Infect Dis 2003; 37:1678-85.Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the human immunodeficiency virus- infected patient: present and future. ...
Loomba R, Liang TJ. Treatment of chronic hepatitis B. Antivir Ther. 2007; 12 (Suppl 3):H33–H41.Davis, GL (1991) Treatment of chronic hepatitis B. Hepatology 14: pp. 567-569Gary L., Davis. (1991) Treatment of chronic hepatitis B. Hepatology 14 :10.1002/hep.v14:3, 567-569 /...
The World Health Organization (WHO) adopted a global strategy in 2016, which aims to reduce the num- ber of new cases of chronic hepatitis B and C by 90% and the number of deaths associated with these diseases by 65% by 2030 [1]. Testing, treatment, and virologic suppression are ...
Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. A randomized controlled trial of recombinant interferon alfa-2b has been initiated in patients with chrome active hepatitis who were negative for serum hep... S Hadziyannis,T Bramou,A Makris,....
Hepatitis B virus: inactive carriers. Virol J. 2005;2:82. Article PubMed PubMed Central CAS Google Scholar Su S. The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan. Hep Intl. 2019;13(2):...
.Influenza like symptoms of fever were observed in 79.30% of the patients treated with IFN α 2b.The side effects were not different between the patients of both groups.Conclusions:The IFN α 2b or IFN α 2b combined with thymosin is efficient to treat patients with chronic hepatitis B.The ...
La Bonda F, Ruiz-Moreno M, Carrero V, et al. Recombinant α-2 interferon treatment in children with chronic hepatitis B. Lancet 1988; 1: 250.Ruiz-Moreno M. Interferon treatment in children with chronic hep- atitis B. J Hepatol 1995; 22:49-51.Ruiz-Moreno M (1995). Interferon ...
Hepatitis B envelope antigen (HBeAg) seroconversion represents an endpoint of treatment of chronic hepatitis B virus (HBV) infections. We have studied whether levels of serum HBV RNA during polymerase inhibitor treatment might be helpful for predicting HBeAg seroconversion. HBV RNA levels were determined...
An important limitation of both 2-drug regimens is that they provide insufficient treatment for people with concomitant chronic hepatitis B who should, therefore, continue 3-drug regimens that include TXF/XTC. Furthermore, all people with HIV who lack immunity to hepatitis B should undergo immunizat...
HBV can also become latent, where antibodies against the hepatitis B core remain detectable while the hepatitis B surface antigen is undetectable [42]. This latency poses significant risk to patients, as it can result in chronic HBV infection, as well as several other complications. The herpes ...